Peptide research · Compound guide
PNC-27 Research Guide
Explore the mechanisms, study findings and evidence limits behind this research topic.
Product artwork identifies the SRP listing. It does not demonstrate safety or clinical benefit. The evidence guide and its sources follow below.
View product label and documentation →
Back to the Research Compound Library
Preclinical cancer-cell and animal research
Evidence reviewed September 13, 2026.
Research overview and identity
PNC-27 is an experimental peptide combining a p53-derived segment with a membrane-penetrating sequence. Its research examines cancer-cell membrane interactions; it should not be described as a proven cancer treatment.
Mechanism under investigation
Primary work proposed interaction with membrane-associated HDM2 and subsequent membrane disruption in selected cancer-cell systems. Selectivity observed in an assay depends on the cells and conditions tested and cannot establish universal tumor selectivity in people.
What the studies report
A 2010 study investigated membrane-associated HDM2 and cell destruction in laboratory models. Subsequent work examined acute myeloid leukemia cells and preclinical transplantation models. These reports support further investigation of a proposed mechanism, not a demonstrated clinical outcome. [1] [2]
Limits of the evidence
Cell-line killing and animal-model findings do not show that a compound safely treats human cancer. Distribution, toxicity, selectivity across normal tissues and clinical effectiveness remain separate questions. A research listing or a pathway graphic does not substitute for those data.
Matching research material to a paper
Check the material identity, formulation and analytical methods against the study methods. A product name or milligram amount alone does not demonstrate experimental equivalence. Published research does not establish the identity, purity or potency of a retail batch; batch-specific analytical documentation must be assessed separately.
For laboratory research only. Not for human or veterinary use. This guide is educational and contains no dosing, reconstitution or administration instructions.
Sources and further reading
- Sarafraz-Yazdi et al. (2010): PNC-27 and membrane-associated HDM2
- PNC-27 in preclinical acute myeloid leukemia models (2019)